C4 Therapeutics
CCCC
117 hedge funds and large institutions have $229M invested in C4 Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 13 closing their positions.
852% more call options, than puts
Call options by funds: $200K | Put options by funds: $21K
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
3% more funds holding
Funds holding: 114 → 117 (+3)
2.22% less ownership
Funds ownership: 82.31% → 80.09% (-2.2%)
35% less capital invested
Capital invested by funds: $353M → $229M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$8.29M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.89M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.03M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.93M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$11.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$7.45M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.72M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$4.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BMSSC
126
B. Metzler seel. Sohn & Co
Frankfurt,
Germany
| – | -$129K | -14,700 | Closed |
|
127
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$63K | -7,230 | Closed |
|
128
Wells Fargo
San Francisco,
California
| – | -$54K | -6,209 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | -$17.8K | -2,145 | -98% |
|
130
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$381 | +46 | New |
|
CCCC Hedge Fund Activity: Q4 2022 in Review
117 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2022, worth a combined $229M — down 35% from $353M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CCCC positions and 13 closed out — a net gain of 4 holders — while 42 added to existing stakes and 33 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $8.29M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $11.4M sold.
- 117 institutional investors held C4 Therapeutics (CCCC) as of Q4 2022, up from 114 in Q3 2022.
- Funds reported $229M of C4 Therapeutics stock for Q4 2022, down 35% quarter-over-quarter.
- 17 funds opened new C4 Therapeutics positions in Q4 2022 and 13 closed out, a net change of +4 holders.
- The largest C4 Therapeutics buyer in Q4 2022 was Soleus Capital Management, an estimated $8.29M added.
- The largest C4 Therapeutics seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2022.